Quantcast
Channel: ナカライテスク
Viewing all 1104 articles
Browse latest View live

Olink社 Proseek Multiplex Oncology 1 パネル

$
0
0

1μlのサンプルについて一度に92種類のがんバイオマーカーをアッセイ可能!

web-154Green_logo_OLINK.jpg

 

 

 

 

 

 この製品に関するご意見・ご照会・お問合せはこちら

-The only highly multiplexed assay with no trade-off on data quality
-Quantifies 92 protein biomarkers in 96 samples simultaneously
-Exceptional specificity based on the Proximity Extension Assay
-Consumes only 1 μL – ideal for biomarker studies in precious bio-banked samples such as -serum, plasma, tissue etc.
-High throughput quantification – 9,216 datapoints generated per run
-New biomarker panels are developed and released continuously by Olink Bioscience

 

Proseek Multiplex is based on Proximity Extension Assay (PEA) Technology

Proseek multiplex.JPG

Biomarkers

Adrenomedullin (ADM) Fatty acid binding protein 4 adipocyte (FABP4) Myeloperoxidase (MPO)
Amphiregulin (AR) Fms-related tyrosine kinase 3 ligand (Flt3L) Detection Control (Det Ctrl)
Angiopoietin-1 receptor (TIE2) Folate receptor alpha (FR-alpha) Osteoprotegerin (OPG)
B-cell activating factor (BAFF) Follistatin (FS)
Ovarian cancer-related tumor marker 125 (CA-125)
Betacellulin (BTC)
Galectin-3 (Gal-3)
Incubation Control (Inc Ctrl 2)
CA242 tumor marker (CA242)
Granulocyte-macrophage colony-stimulating factor (GM-CSF) Placenta Growth Factor (PlGF)
Carbonic Anhydrase IX (CAIX)
Incubation Control (Inc Ctrl 1)
Platelet endothelial cell adhesion molecule (PECAM-1)
Carcinoembryonic antigen (CEA)
Growth Hormone (GH)
Platelet-derived growth factor subunit B (PDGF subunit B)
Caspase-3 (CASP-3)
Growth/differentiation factor 15 (GDF-15)
Prolactin (PRL)
Cathepsin D (CTSD)
Heparin-binding EGF-like growth factor (HB-EGF)
Prostasin (PRSS8)
C-C motif chemokine 19 (CCL19)
Hepatocyte growth factor (HGF)
Prostate-specific antigen (PSA)
C-C motif chemokine 21 (CCL21)
Hepatocyte growth factor receptor (HGF receptor)
Receptor tyrosine-protein kinase ErbB-2 (ErbB2/Her2)
C-C motif chemokine 24 (CCL24)
Interferon gamma (IFN-gamma)
Receptor tyrosine-protein kinase ErbB-3 (ErbB3/Her3)
CD40 ligand (CD40-L)
Interleukin 1 receptor antagonist protein (IL-1ra)
Receptor tyrosine-protein kinase ErbB-4 (ErbB4/Her4)
C-X-C motif chemokine 10 (CXCL10)
Interleukin 12 (IL-12)
Regenerating islet-derived protein 4 (REG-4)
C-X-C motif chemokine 11 (CXCL11)
Interleukin 17 receptor B (IL17RB)
Stem cell factor (SCF)
C-X-C motif chemokine 13 (CXCL13)
Interleukin 2 (IL-2)
Tartrate-resistant acid phosphatase type 5 (TR-AP)
C-X-C motif chemokine 5 (CXCL5)
Interleukin 2 receptor subunit alpha (IL2RA)
Thrombopoietin (THPO)
C-X-C motif chemokine 9 (CXCL9)
Interleukin 4 (IL-4)
Tissue Factor (TF)
Cystatin B (CPI-B)
Interleukin 6 (IL-6)
Transforming growth factor alpha (TGF-alpha)
Early activation antigen CD69 (CD69)
Interleukin 6 receptor subunit alpha (IL6RA)
Transforming growth factor beta 1 (TGF-beta-1)
Epidermal growth factor (EGF)
Interleukin 7 (IL-7)
Tumor necrosis factor alpha (TNF)
Epidermal growth factor receptor (EGFR)
Interleukin 8 (IL-8)
Tumor necrosis factor ligand superfamily member 14 (TNFSF14)
Epididymal secretory protein E4 (HE4)
Kallikrein-11 (hK11)
Tumor necrosis factor ligand superfamily member 8 (CD30-L)
Epiregulin (EPR)
Kallikrein-6 (KLK6)
Tumor necrosis factor receptor 1 (TNF-RI)
Epithelial cell adhesion molecule (Ep-CAM)
Macrophage colony-stimulating factor 1 (CSF-1)
Tumor necrosis factor receptor 2 (TNF-R2)
Erythropoietin (EPO)
Matrix metalloproteinase-3 (MMP-3)
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4)
E-selectin (CD62E)
Melanoma-derived growth regulatory protein (MIA)
Tumor necrosis factor receptor superfamily member 6 (FAS)
Estrogen receptor (ER)
MHC class I polypeptide-related sequence A (MIC-A)
Urokinase plasminogen activator surface receptor (U-PAR)
Extension Control (Ext Ctrl)
Midkine (MK)
Vascular endothelial growth factor A (VEGF-A)
Extracellular matrix metalloproteinase inducer (EMMPRIN) Monocyte chemotactic protein-1 (MCP-1)
Vascular endothelial growth factor D (VEGF-D)
Fas antigen ligand (FasL)
Myeloid differentiation primary response protein MyD88 (MYD88) Vascular endothelial growth factor receptor 2 (VEGFR-2)

 

 この製品に関するご意見・ご照会・お問合せはこちら

 

 

 

 

 

 


Tocris社 2013年4月新製品

$
0
0

tocris-logo-web.jpg

 

 

 

 

 

 この製品に関するご意見・ご照会・お問合せはこちら

 

 New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules, peptides and antibodies being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can.

 

Cat.No. Product Name Activity
4782 Org 25543 hydrochloride Potent and selective GlyT2 inhibitor
4615 MEDICA 16 FFA1 (GPR40) agonist. Also inhibits ATP citrate lyase
3496 BX 471 Potent, selective CCR1 antagonist
3094 Flavopiridol hydrochloride Cyclin-dependent kinase inhibitor
4853 8-pCPT-2-O-Me-cAMP-AM Selective Epac activator; cell-permeable analog of 8CPT-2Me-cAMP (Cat. No. 1645)
4629 GSK2578215A Potent, selective LRRK2 inhibitor; brain penetrant
4863 CA 074 Selective cathepsin B inhibitor
4857 Amlexanox Inhibitor of TBK1 and IKKε; antiallergic agent
4852 Carbetocin Oxytocin analog
4823 PF 05212384 Potent and selective dual PI 3-kinase/mTOR inhibitor
4821 PF 03814735 Aurora kinase A and B inhibitor
4820 PF 04691502 Dual PI 3-K/mTOR inhibitor
4818 PF 04418948 Potent and selective EP2 receptor antagonist
4810 BAM 7 Selective Bax activator; induces Bax-mediated apoptosis
4565 ML 228 HIF pathway activator
3946 TNP Inhibitor of IP6K; also inhibits IP3K
4817 SKPin C1 Inhibits Skp2-mediated p27 degradation; induces cell cycle arrest
4757 Latanoprost FP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptors
 

  

この製品に関するご意見・ご照会・お問合せはこちら

臨時休業のお知らせ

$
0
0

設立55周年社内行事のため、誠に勝手ながら2013年5月24日(金)は臨時休業とさせていただきますことをお知らせいたします。

Tocris社 2013年5月新製品

$
0
0

tocris-logo-web.jpg

 

 

 

 

 この製品に関するご意見・ご照会・お問合せはこちら

 

 

New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules, peptides and antibodies being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can.

 

                                                                                       

Cat.No. Product Name Activity
4878 H2L5186303 Potent and selective LPA2 receptor antagonist
4864 NS 6180 Potent KCa3.1 channel blocker
4774 BMS 536924 Dual IR/IGF1R inhibitor
4769 VUF 10460 Selective H4 agonist
4727 GS 6201 Selective A2B antagonist

 

 

この製品に関するご意見・ご照会・お問合せはこちら

 

培地交換が2日~3日に1回でOK FGF2徐放ビーズ StemBeads モニター募集

プロテインアッセイCBB溶液(Ready To Use)

$
0
0

ナカライテスク社 プロテインアッセイCBB溶液(Ready To Use)

本製品は、使用時に希釈の手間不要なready to useタイプのタンパク質定量試薬です。

特長
  • Ready To Useタイプで操作の手間や時間を短縮
  • ランニングコストを低減
測定範囲

従来のProtein Assay CBB Solution(5x)と測定範囲は同じです

アッセイ方法スタンダード法マイクロ法
試験管 マイクロプレート 試験管 マイクロプレート
測定範囲 0.2~1.4 mg / ml  0.2~1.0 mg / ml  2.5~25μg / ml 
混合 検量線用標準液
もしくは被検液
 50μl  10μl  1 ml  150μl
CBB溶液(本品)  2.5 ml  200μl  1 ml  100μl
実施例

■マイクロプレートスタンダードアッセイ法によりBSAを定量 

  P1jisirei-grafu.gif
CBB溶液(Ready To Use)は、他社製品と同様の測定範囲を示します。

■使用量が少量

   P1jisirei-zu.gif
上図のとおり、マイクロプレートスタンダードアッセイ法では、当社製品は少ない試薬量でアッセイでき、ランニングコストを低減できます。
 

▲戻る

価格表
製品名規格貯法製品番号容量価格
Protein Assay CBB Solution(Ready To Use) SP 冷蔵 11617-71 1 L 14,500

 ※記載の内容は、'13年3月現在の情報に基づいております。

InvivoGen社細胞商品輸送条件変更のお知らせ

$
0
0

平素はInvivoGen社商品のご愛顧を賜り厚くお礼申し上げます。
さて、この度InvivoGen社細胞商品について品質安定のため、輸送条件が凍結状態での輸送に変更されますので、お知らせします。
現在の細胞を休眠状態にしたうえでの室温輸送から、凍結状態、ドライアイス梱包での輸送に変更します。

 

実施日

2013年3月15日(金) InvivoGen社出荷分より

 

変更目的

品質安定のため

 

変更内容

細胞を休眠状態にしたうえでの室温輸送
  ↓
細胞を凍結状態、ドライアイス梱包での輸送

 

取扱上の注意

当該商品がお手元に到着次第、直ぐに細胞培養をお願いします。

 

Invivo1303.jpg

 

対象商品
商品名メーカー製品番号
293/hMD2-CD14 293-hmd2cd14
293/hNOD1 293-hnod1
293/hNOD2 293-hnod2
293/hTLR1-HA 293-htlr1ha
293/hTLR2 293-htlr2
293/hTLR2-TLR6 293-htlr2/6
293/hTLR2-CD14 293-htlr2cd14
293/hTLR2-HA 293-htlr2ha
293/hTLR3 293-htlr3
293/hTLR3-HA 293-htlr3ha
293/hTLR4A 293-htlr4a
293/hTLR4-HA 293-htlr4ha
293/hTLR4A-MD2-CD14 293-htlr4md2cd14
293/hTLR5 293-htlr5
293/hTLR5-CD14 293-htlr5cd14
293/hTLR5-HA 293-htlr5ha
293/hTLR6-HA 293-htlr6ha
293/hTLR10-HA 293-htlr10ha
293/LacZ 293-lacz
293/mNOD1 293-mnod1
293/mNOD2 293-mnod2
293/mTLR1 293-mtlr1
293/mTLR1-TLR2 293-mtlr1/2
293/mTLR2 293-mtlr2
293/mTLR2-TLR6 293-mtlr2/6
293/mTLR3 293-mtlr3
293/mTLR4 293-mtlr4
293/mTLR4-MD2-CD14 293-mtlr4md2cd14
293/mTLR5 293-mtlr5
293/mTLR6 293-mtlr6
293/mTLR9 293-mtlr9
293/null 293-null
293XL/hTLR7 293xl-htlr7
293XL/hTLR7-HA 293xl-htlr7ha
293XL/hTLR8 293xl-htlr8
293XL/hTLR8-HA 293xl-htlr8ha
293XL/hTLR9 293xl-htlr9
293XL/hTLR9-HA 293xl-htlr9ha
293XL/mTLR7 293xl-mtlr7
293XL/null 293xl-null
HEK-Blue™ CD40L cells hkb-cd40
HEK-Blue™ CD40L kit hkb-cd40-kit
HEK-Blue™ hMD2-CD14 cells hkb-hmdcd
HEK-Blue™ hNOD1 cells hkb-hnod1
HEK-Blue™ hNOD2 cells hkb-hnod2
HEK-Blue™ hTLR2 cells hkb-htlr2
HEK-Blue™ hTLR3 cells hkb-htlr3
HEK-Blue™ hTLR4 cells hkb-htlr4
HEK-Blue™ hTLR5 cells hkb-htlr5
HEK-Blue™ hTLR7 cells hkb-htlr7
HEK-Blue™ hTLR8 cells hkb-htlr8
HEK-Blue™ hTLR9 cells hkb-htlr9
HEK-Blue™ IFN-α/β cells hkb-ifnab
HEK-Blue™ IFN-γ cells hkb-ifng
HEK-Blue™ IL-18/1L-1β cells hkb-il18
HEK-Blue™ IL-18/IL-1β kit hkb-il18-kit
HEK-Blue™ IL-1β cells hkb-il1b
HEK-Blue™ IL-1β kit hkb-il1b-kit
HEK-Blue™ IL-33/IL-1β cells hkb-il33
HEK-Blue™ IL-6 cells hkb-il6
HEK-Blue™ IL-6 kit hkb-il6-kit
HEK-Blue™ mNOD1 cells hkb-mnod1
HEK-Blue™ mNOD2 cells hkb-mnod2
HEK-Blue™ mTLR2 cells hkb-mtlr2
HEK-Blue™ mTLR3 cells hkb-mtlr3
HEK-Blue™ mTLR4 cells hkb-mtlr4
HEK-Blue™ mTLR5 cells hkb-mtlr5
HEK-Blue™ mTLR7 cells hkb-mtlr7
HEK-Blue™ mTLR8 cells hkb-mtlr8
HEK-Blue™ mTLR9 cells hkb-mtlr9
HEK-Blue™ Null1 cells hkb-null1
HEK-Blue™ Null1-k cells hkb-null1k
HEK-Blue™ Null1-v cells hkb-null1v
HEK-Blue™ Null2 cells hkb-null2
HEK-Blue™ Null2-k cells hkb-null2k
HEK-Blue™ IL-4/IL-13 cells hkb-stat6
HEK-Blue™ IL-4/IL-13 kit hkb-stat6-kit
HEK-Blue™ TGF-β cells hkb-tgfb
HEK-Blue TGF-β kit hkb-tgfb-kit
HEK-Blue™ TNF-α/IL-1β cells hkb-tnfil1
HEK-Blue™TNF-α/IL-1β kit hkb-tnfil1-kit
HEK-Dual™ IFN-γ cells hkd-ifng
HEK-Dual TNFα cells hkd-tnfa
Jurkat-Dual™ cells jktd-isnf
C3H/TLR4mut MEF mef-c3h4m
C3H/WT MEF mef-c3hwt
C57/WT MEF mef-c57wt
RAW-Blue™ ISG cells raw-isg
RAW-Lucia™ ISG Cells rawl-isg
RAW-Blue™ cells raw-sp
PlasmoTest™ rep-pt1
PlasmoTest™ rep-pt2
Ramos-Blue™-defMyD cells rms-dmyd
Ramos-Blue™ cells rms-sp
THP1-defASC thp-dasc
THP1-Dual™ Cells thpd-nfis
THP1-defNLRP3 thp-dnlp
THP1-Blue™ ISG Cells thp-isg
THP1-Lucia™ ISG Cells thpl-isg
THP1-Lucia™ Cells thpl-nfkb
THP1-Blue™ NF-κB Cells thp-nfkb
THP1-Null thp-null
THP1 -XBlue™-CD14 cells thpx-cd14sp
THP1-XBlue™-defMyD cells thpx-dmyd
THP1 -XBlue™-MD2-CD14 cells thpx-mdcdsp
THP1-XBlue™ cells thpx-sp

 

コスモシールCholester 天然物・抽出物の分析に効果を発揮!(LabFab Chemicals 2013 April)

$
0
0

コスモシールCholester は、コレステロール由来の固定相構造を有するためC18 カラムで分離できない化合物に対し分離を改善できる逆相クロマトグラフィー用カラムです。今回はC18 カラムでは分離できないコーヒーの有効成分の分析例をご紹介します。

記事は

こちら→pdf.gif

(440KB)

 


トリアゾール結合型HILIC カラム(LabFab Chemicals 2013 April)

$
0
0

コスモシールHILIC は、トリアゾールを結合させることにより親水性相互作用に加えて陰イオン交換能を有し
ます。この親水性相互作用と陰イオン交換能によりユニークな保持挙動や分離能を示します。

記事は

こちら→pdf.gif

(179KB)

 

ユビキチン研究関連受託サービス取り扱い開始

$
0
0

LifeSensors社のユビキチン研究関連受託サービス2件の取り扱いを開始しました。

 

  • ユビキチンタンパク質マイクロアレイサービスはこちら
  • モノユビキチン化ペプチド受託合成サービスはこちら

LabFab News Vol.11 April 2013 発行

$
0
0
掲載タイトル
StemCulture StemBeads FGF2
ナカライテスク 細胞保存液 Cell Reservoir One(ガラス化法用)
Tocris 幹細胞研究関連試薬
LifeSensors モノユビキチン化ペプチド
InvivoGen ワクチンアジュバント
Atlas Antibodies ヒト細胞 / 組織染色用抗体
Biotium Mix-n-Stain™ Antibody Labeling Kit
Santa Cruz モノクローナル抗体 新製品
ナカライテスク りん酸緩衝生理食塩水(KCl 不含)(pH 7.2)
ナカライテスク COSMOSIL® 2.5HILIC

PDF版ダウンロードはこちら(2.1MB)

ご請求はこちら

 

lab_48_200.jpg

 

 

 

LabFab News Chemicals April 2013 発行

$
0
0
掲載タイトル
Ark Pharm 光学活性化合物
Apollo Scientific ふっ素化合物
Strem 鈴木―宮浦カップリング反応試薬
Strem メタセシス触媒
SiliCycle® SiliaMetS®(金属スカベンジャー)
ナカライテスク e-Nacalai Search Version構造式検索
ナカライテスク COSMOSIL® HILICカラム
ナカライテスク COSMOSIL® Cholesterカラム
LKT Laboratories 天然物
U.S. PHARMACOPEIA U.S. PHARMACOPEIA Reference Standards

PDF版ダウンロードはこちら(2.0MB)

ご請求はこちら

 

lab_47_200.jpg

LifeSensors社脱ユビキチン化酵素(DUB)ノックダウン細胞株

$
0
0

USP7、USP14、USP19、USP9x ノックダウン HeLa 細胞

 

LSlogo-Vspot copy  090904.JPG

 

 

 

 

 

 

 

 この製品に関するご意見・ご照会・お問合せはこちら

RNAi is the major approach for studying a targeted gene function with high specificity and selectivity as a reliable alternative to laborious knockout strategies.

 

LifeSensors is offering SilenciX®, gene-specific knock-down cell lines ‘silencing’ DUBs and/or other important proteins of interest using a unique siRNA delivery system developed by tebu-bio Laboratories*. Based on EBV-replication, SilenciX ensures chromosome-like replication without integration in the genome. Reinforced by an optimal hygromycin selection, this loss-of-function model comes with exceptional features determined by three major factors:

·        Targeting - specific and efficient

·        Stability - homogenous and constant knockdown

·        No off-target effects - genome and transcriptome integrity

 

 

Lifesensors silencix.JPG

Main benefits:

  • Efficiency
    - Validation performed by qPCR
    - KD level guarantee: >70%
  • Specificity
  • High Stability and long term culture: 3-12 months
  • No off-target effects
  • Non-viral genome integrity
  • Safe
  • Ready to Use (RTU)

 

 


SilenciX® employs a pEBV-derived plasmid delivery system designed to deliver optimal and constant siRNA levels without off-target effects (Biard, 2007). The Epstein-Barr (EBV)-based vector is anchored to chromosomes and replicates as a replicon without any integration in the genome. Reinforced by optimal hygromycin selection, the number of vectors is perfectly maintained. This avoids saturation of the RNAi machinery resulting in specific and homogeneous knockdown of the desired target.

 

Comparison to traditional RNAi approaches:

  siRNA shRNA SilenciX

Human and rodent cell lines
Stability 2-3 days Several months Several months; start each experiment with the same cell batch - just thaw the vial
Efficiency >70% validation by qPCR
Production time Few days, controlling each experiment 5 weeks 2/3 days
Reproducibility no Yes, with experience High reproducibility, Homogeneous population

 


Applications of specific knock-down cellular model using SilenciX® technology



  • A ready-to-use and stable cellular model of loss-of-function.
  • Reliable, functional RNAi assay to rapidly screen and analyze new therapeutics.
  • Powerful technology for target validation.
  • Cell-based assay development for HTS. Mimic disease phenotypes with target depletion.
  • Secondary screening: confirmed hits can be tested in a functional assays offered by SilenciX® catalog and custom cell lines.

 

PRODUCT INFORMATION
For each cell line, you receive:

• One vial of target specific SilenciX® cells

• One vial of control SilenciX® cells (transfected with a non-relevant shRNA sequence)

• Specification sheets with qPCR quality controls and details of shRNA sequence

•   Complete user manual



References

Despras E, Pfeiffer P, Salles B, Calsou P, Kuhfittig-Kulle S, Angulo JF, Biard DS. Long-term XPC silencing reduces DNA double-strand break repair. Cancer Res. 2007 Mar 15;67(6):2526-34.

 

Product Name Cat No Volume
USP14 HeLa SilenciX SLX-00163 1 kit
USP19 HeLa SilenciX SLX-00164 1 kit
USP7 HeLa SilenciX SLX-00159 1 kit
USP9X HeLa SilenciX SLX-00160 1 kit

*SilenciX® is a registered trademark of tebu-bio; technology licensed from the CEA.

 この製品に関するご意見・ご照会・お問合せはこちら


 

InvivoGen社 マルチ-TLR アゴニスト

$
0
0

TLR2かつ/またはTLR7に作用するアゴニスト

InvivoGen-Logo-web.jpg

 

 

 

 

 

 

 この製品に関するご意見・ご照会・お問合せはこちら

 

Toll-like receptors (TLRs) are the best studied pattern recognition receptors (PRRs) and their importance in stimulating innate and adaptive immunity is now well established.
TLRs are sensors of microbial components as well as host-derived endogenous molecules released by injured tissues. TLRs play a critical role in defense against invading pathogens but are also involved in other serious pathological processes, such as tumorigenesis [1]. In view of this, TLR agonists have great potential as immunotherapeutics or vaccine adjuvants for the treatment of infectious diseases, cancer and autoimmune diseases.

 

PRR_combination.jpg

 

One of the most successful empiric vaccines ever developed, the live attenuated yellow fever vaccine YF-17D, activates immune cells via multiple TLRs [2]. In the same line, microbial products, such as Coley’s toxin (a mixture of killed Streptococcus pyogenes and Serratia marcescens bacteria) and Bacille Calmette-Guérin (BCG, an attenuated strain of Mycobacterium bovis), which have been used as anticancer agents with some success, induce the host immune system through the activation of several TLRs. Studies have demonstrated that YF-17D and BCG efficacy requires a Th1 cytokine response which promotes antigen-specific cytotoxic T cells [2, 3].

 

Today, very few TLR agonists are approved for clinical use as stand-alone agents or adjuvants [4]. One of the major challenges of cancer immunotherapy is the reversal of tumor-driven immune suppression. Tumor cells release soluble factors leading to tumor infiltration by immune cells and their convertion into potent immunosuppressive cells. Among the immune suppressor cells, myeloid-derived suppressor cells (MDSCs) are the focus of extensive studies. MDSCs release additional soluble factors that stimulate tumor growth, induce regulatory T cells and suppress CD8+ T cells, thus impairing tumor surveillance and antitumor responses [5]. TLR3 or TLR9 agonists, which elicit strong IFN-α responses, have been shown to induce MDSC maturation and loss of suppressive functions, in contrast to TLR4 agonists which support MDSC suppressive functions [6].

 

PamadiFectin_pathway.jpg

 

 

Schematic representation of innate immune signaling pathways activated by PamadiFectin™ (CL553), a multi-PRR agonist that activates TLR2, TLR7 and nucleic acid sensors when complexed with dsDNA, for example.

 

Given that TLRs are expressed in different cellular compar tments, by different cell types and that they trigger different signaling pathways, combining TLR agonists can act in synergy to promote Th1-type immunity. Encouraging clinical results have been reported with the combination of BCG and the TLR7 agonist Imiquimod in melanoma patients [7]. Furthermore, vaccination studies have demonstrated that the combination of Imiquimod and MPL, a TLR4 ligand, elicits synergistic increases in antigen-specific neutralizing antibodies compared to a single TLR ligand [8].

 

The combination of TLR agonists with agonists for other PRRs, such as the sensors of nucleic acids RIG-I/MDA-5, IFI16 and cGAS, may fur ther enhance the immune response against cancer and infectious diseases.
With this perspective, InvivoGen has developed multi-PRR agonists that activate TLR2 and/or TLR7 and can complex nucleic acids, such as double-stranded DNA, leading to additional recognition by cytosolic DNA sensors (CDSs). These molecules have been shown to induce a strong immune response in a murine melanoma cancer model and in vaccination studies.

 

By mimicking the potent natural immuno-stimuli that are viruses and bacteria, multi-PRR ligands represent an interesting new class of agents in cancer immunotherapy or vaccination. However, further studies are needed to develop the best PRR agonist combinations for a given application.

 

1. Rakoff-Nahoum S. & Medzhitov R., 2007. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 317(5834):124-7.
2. Querec T. et al., 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 tostimulate polyvalent immunity. J Exp Med. 203(2):413-24.
3. Saint F. et al., 2001. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol. 166(6):2142-7.
4. Galluzzi L. et al., 2012. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 1(5): 699–716.
5. Gabrilovich DI. et al., 2012. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 12(4):253-68.
6. Lindau D. et al., 2013. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 138(2):105-15.
7. Kidner TB. et al., 2012. Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother. 35(9):716-20.
8. Kasturi SP. et al., 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 470(7335):543-7.

 

 Multi-PRR Ligands Products

Dual TLR Agonists
CL401 TLR2 & TLR7 Ligand 500 µg
Adilipoline™ (CL413) TLR2 & TLR7 Ligand 500 µg
CL531 TLR2 & TLR7 Ligand 500 µg
CL572 Human TLR2 & mouse and humanTLR7 Ligand 500 µg
TLR Agonists & Nucleic Acid Carriers
CL419 TLR2 Ligand 500 µg
AdiFectin™ (CL347) TLR7 Ligand 500 µg
PamadiFectin™ (CL553) TLR2 & TLR7 Ligand 500 µg

 

この製品に関するご意見・ご照会・お問合せはこちら

 

LifeSensors社 SUMO研究用試薬

$
0
0

SUMO化酵素、脱SUMO化酵素、SUMO誘導体

LSlogo-Vspot copy  090904.JPG

 

 

 

 

 

 

 

 この製品に関するご意見・ご照会・お問合せはこちら

Deconjugating Enzymes

 Product Name
CATALOG#
 Volume
SENP1core DB701 25 ug
SENP2core    4020    250 unit
500 unit
1000 unit
5000 unit
SENP6core DB703 25 ug

 

Deconjugating Enzyme Substrates

Product Name CATALOG# Volume
SUMO1-AMC SI420 50 ug
SUMO2-AMC SI520 50 ug
SUMO2-aminoluciferin SI560 50 ug
SUMO2-Rhodamine SI530 50 ug

 

Conjugating Enzymes

Product Name CATALOG# Volume
SUMO E1 SU101 25 ug
UBE2I, His6 (Ubc9)         UB228H 3 nmoles

 

SUMO

Product Name CATALOG# Volume
SUMO-2 (human, recombinant) SU202 500 ug

 

 この製品に関するご意見・ご照会・お問合せはこちら


Olink社 Proseek Multiplex Oncology 1 パネル

$
0
0

1μlのサンプルについて一度に92種類のがんバイオマーカーをアッセイ可能!

web-154Green_logo_OLINK.jpg

 

 

 

 

 

 この製品に関するご意見・ご照会・お問合せはこちら

-The only highly multiplexed assay with no trade-off on data quality
-Quantifies 92 protein biomarkers in 96 samples simultaneously
-Exceptional specificity based on the Proximity Extension Assay
-Consumes only 1 μL – ideal for biomarker studies in precious bio-banked samples such as -serum, plasma, tissue etc.
-High throughput quantification – 9,216 datapoints generated per run
-New biomarker panels are developed and released continuously by Olink Bioscience

 

Proseek Multiplex is based on Proximity Extension Assay (PEA) Technology

Proseek multiplex.JPG

Biomarkers

Adrenomedullin (ADM) Fatty acid binding protein 4 adipocyte (FABP4) Myeloperoxidase (MPO)
Amphiregulin (AR) Fms-related tyrosine kinase 3 ligand (Flt3L) Detection Control (Det Ctrl)
Angiopoietin-1 receptor (TIE2) Folate receptor alpha (FR-alpha) Osteoprotegerin (OPG)
B-cell activating factor (BAFF) Follistatin (FS)
Ovarian cancer-related tumor marker 125 (CA-125)
Betacellulin (BTC)
Galectin-3 (Gal-3)
Incubation Control (Inc Ctrl 2)
CA242 tumor marker (CA242)
Granulocyte-macrophage colony-stimulating factor (GM-CSF) Placenta Growth Factor (PlGF)
Carbonic Anhydrase IX (CAIX)
Incubation Control (Inc Ctrl 1)
Platelet endothelial cell adhesion molecule (PECAM-1)
Carcinoembryonic antigen (CEA)
Growth Hormone (GH)
Platelet-derived growth factor subunit B (PDGF subunit B)
Caspase-3 (CASP-3)
Growth/differentiation factor 15 (GDF-15)
Prolactin (PRL)
Cathepsin D (CTSD)
Heparin-binding EGF-like growth factor (HB-EGF)
Prostasin (PRSS8)
C-C motif chemokine 19 (CCL19)
Hepatocyte growth factor (HGF)
Prostate-specific antigen (PSA)
C-C motif chemokine 21 (CCL21)
Hepatocyte growth factor receptor (HGF receptor)
Receptor tyrosine-protein kinase ErbB-2 (ErbB2/Her2)
C-C motif chemokine 24 (CCL24)
Interferon gamma (IFN-gamma)
Receptor tyrosine-protein kinase ErbB-3 (ErbB3/Her3)
CD40 ligand (CD40-L)
Interleukin 1 receptor antagonist protein (IL-1ra)
Receptor tyrosine-protein kinase ErbB-4 (ErbB4/Her4)
C-X-C motif chemokine 10 (CXCL10)
Interleukin 12 (IL-12)
Regenerating islet-derived protein 4 (REG-4)
C-X-C motif chemokine 11 (CXCL11)
Interleukin 17 receptor B (IL17RB)
Stem cell factor (SCF)
C-X-C motif chemokine 13 (CXCL13)
Interleukin 2 (IL-2)
Tartrate-resistant acid phosphatase type 5 (TR-AP)
C-X-C motif chemokine 5 (CXCL5)
Interleukin 2 receptor subunit alpha (IL2RA)
Thrombopoietin (THPO)
C-X-C motif chemokine 9 (CXCL9)
Interleukin 4 (IL-4)
Tissue Factor (TF)
Cystatin B (CPI-B)
Interleukin 6 (IL-6)
Transforming growth factor alpha (TGF-alpha)
Early activation antigen CD69 (CD69)
Interleukin 6 receptor subunit alpha (IL6RA)
Transforming growth factor beta 1 (TGF-beta-1)
Epidermal growth factor (EGF)
Interleukin 7 (IL-7)
Tumor necrosis factor alpha (TNF)
Epidermal growth factor receptor (EGFR)
Interleukin 8 (IL-8)
Tumor necrosis factor ligand superfamily member 14 (TNFSF14)
Epididymal secretory protein E4 (HE4)
Kallikrein-11 (hK11)
Tumor necrosis factor ligand superfamily member 8 (CD30-L)
Epiregulin (EPR)
Kallikrein-6 (KLK6)
Tumor necrosis factor receptor 1 (TNF-RI)
Epithelial cell adhesion molecule (Ep-CAM)
Macrophage colony-stimulating factor 1 (CSF-1)
Tumor necrosis factor receptor 2 (TNF-R2)
Erythropoietin (EPO)
Matrix metalloproteinase-3 (MMP-3)
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4)
E-selectin (CD62E)
Melanoma-derived growth regulatory protein (MIA)
Tumor necrosis factor receptor superfamily member 6 (FAS)
Estrogen receptor (ER)
MHC class I polypeptide-related sequence A (MIC-A)
Urokinase plasminogen activator surface receptor (U-PAR)
Extension Control (Ext Ctrl)
Midkine (MK)
Vascular endothelial growth factor A (VEGF-A)
Extracellular matrix metalloproteinase inducer (EMMPRIN) Monocyte chemotactic protein-1 (MCP-1)
Vascular endothelial growth factor D (VEGF-D)
Fas antigen ligand (FasL)
Myeloid differentiation primary response protein MyD88 (MYD88) Vascular endothelial growth factor receptor 2 (VEGFR-2)

 

 この製品に関するご意見・ご照会・お問合せはこちら

 

 

 

 

 

 

Tocris社 2013年3月新製品

$
0
0

tocris-logo-web.jpg

 

 

 

 

 

この製品に関するご意見・ご照会・お問合せはこちら 

 

New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules, peptides and antibodies being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can.

 

Cat.No. Product Name Activity
4833 Levonorgestrel Synthetic progesterone analog
4815 3-Cyano-7-ethoxycoumarin Fluorescent cytochrome P450 substrate
4547 ACHP Selective IKKα and IKKβ inhibitor
4846 Apicidin Histone deacetylase inhibitor
4804 APETx2 ASIC3 channel blocker
4791 Candesartan AT1 receptor antagonist
4779 GRI 977143 Selective LPA2 agonist; antiapoptotic
4748 ML 221 Apelin receptor (APJ) antagonist
4571 A 867744 Positive allosteric modulator of α7 nAChR
4811 TAT 14 Nrf2 pathway activator; blocks Nrf2/Keap1 interaction
4792 Candesartan cilexetil Prodrug of candesartan, an AT1 receptor antagonist
4755 Q94 hydrochloride Negative allosteric modulator at PAR1 receptor
4751 FSLLRY-NH2 PAR2 peptide antagonist
4746 ML SA1 Activator of TRPML channels
4744 P11 Potent antagonist of αvβ3-vitronectin interaction; antiangiogenic
4677 CYM 50260 Potent and selective S1P4 agonist
4638 Pam2CSK4 Biotin Biotinylated Pam2CSK4 (Cat. No. 4637)
4636 Pam3CSK4 Biotin Biotinylated Pam3CSK4 (Cat. No. 4633)
4345 TC-C 14G Potent, high affinity CB1 receptor inverse agonist
4012 SR 140333 Potent NK1 receptor antagonist
3920 AMG 548 Potent and selective p38α inhibitor
3839 HPI 1 Inhibits Hedgehog signaling
4541 SGC 0946 Highly potent and selective DOT1L inhibitor; cell permeable

 

 

この製品に関するご意見・ご照会・お問合せはこちら

Tocris社 2013年4月新製品

$
0
0

tocris-logo-web.jpg

 

 

 

 

 

 この製品に関するご意見・ご照会・お問合せはこちら

 

 New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules, peptides and antibodies being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can.

 

Cat.No. Product Name Activity
4855 WIKI4 Tankyrase inhibitor; inhibits Wnt signaling
4847 PluriSln 1 Inhibitor of SCD1; selectively eliminates undifferentiated hPSCs from culture
4813 Paprotrain Reversible inhibitor of MKLP-2
4812 ADWX 1 Potent and selective KV1.3 channel blocker
4762 MIM1 Mcl-1 inhibitor; proapoptotic
4489 DBZ γ-secretease inhibitor; inhibits Notch pathway
4373 CMPDA Positive allosteric modulator of GluA2 receptors
3378 EIPA Inhibits TRPP3-mediated currents; also inhibits the Na+/H+ exchanger (NHE)
4782 Org 25543 hydrochloride Potent and selective GlyT2 inhibitor
4615 MEDICA 16 FFA1 (GPR40) agonist. Also inhibits ATP citrate lyase
3496 BX 471 Potent, selective CCR1 antagonist
3094 Flavopiridol hydrochloride Cyclin-dependent kinase inhibitor
4853 8-pCPT-2-O-Me-cAMP-AM Selective Epac activator; cell-permeable analog of 8CPT-2Me-cAMP (Cat. No. 1645)
4629 GSK2578215A Potent, selective LRRK2 inhibitor; brain penetrant
4863 CA 074 Selective cathepsin B inhibitor
4857 Amlexanox Inhibitor of TBK1 and IKKε; antiallergic agent
4852 Carbetocin Oxytocin analog
4823 PF 05212384 Potent and selective dual PI 3-kinase/mTOR inhibitor
4821 PF 03814735 Aurora kinase A and B inhibitor
4820 PF 04691502 Dual PI 3-K/mTOR inhibitor
4818 PF 04418948 Potent and selective EP2 receptor antagonist
4810 BAM 7 Selective Bax activator; induces Bax-mediated apoptosis
4565 ML 228 HIF pathway activator
3946 TNP Inhibitor of IP6K; also inhibits IP3K
4817 SKPin C1 Inhibits Skp2-mediated p27 degradation; induces cell cycle arrest
4757 Latanoprost FP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptors
 

  

この製品に関するご意見・ご照会・お問合せはこちら

Tocris社 2013年5月新製品

$
0
0

tocris-logo-web.jpg

 

 

 

 

 この製品に関するご意見・ご照会・お問合せはこちら

 

 

New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules, peptides and antibodies being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can.

 

                                                                                               

Cat.No. Product Name Activity
4878 H2L5186303 Potent and selective LPA2 receptor antagonist
4864 NS 6180 Potent KCa3.1 channel blocker
4774 BMS 536924 Dual IR/IGF1R inhibitor
4769 VUF 10460 Selective H4 agonist
4727 GS 6201 Selective A2B antagonist

 

 

この製品に関するご意見・ご照会・お問合せはこちら

 

プロテインアッセイCBB Clean Up Kit

$
0
0

ナカライテスク社 プロテインアッセイCBB Clean Up Kit

本製品の使用により、CBB法において、高濃度の界面活性剤や塩類、変性剤を含む溶液のタンパク質定量が可能です。操作は簡単で、タンパク質沈殿法により、これらの妨害物質を除去でき、測定用サンプルの調製が可能です。

特長
  • わずか5分の実操作で妨害物質を除去
使用例

■SDS-PAGE用試料緩衝液に溶解しているタンパク質の定量
妨害物質である還元剤、界面活性剤を共に含む試料緩衝液中のタンパク質(BSA)を測定した結果を示します。A社除去キット使用時には、定量性が得られませんでしたが、本製品では定量性が得られており、除去効果が確認できました。

   P2-zu.gif
実施例

以下に妨害物質の例を示します。水色の列は、直接サンプルをCBB法で測定しても影響を与えない妨害物質の最大濃度を示し、紫色の列は本製品を使用した場合の最大濃度を示しています。界面活性剤、変性剤、塩類では妨害物質の影響が大幅に減少しています。
*キレート剤含有または酸性溶液(pH約5以下)の場合、中和もしくは表記載濃度まで希釈してからご使用ください。
   使用前に製品添付文書をご参照ください。

妨害物質直接 CBB法本製品使用時妨害物質直接 CBB法本製品使用時
界面活性剤 変性剤
Brij35 0.05% 7.5% Ammonium Sulfate 2M 1M
NP-40 0.05% 10% Arginine・Na 2M 2M
Octylβ-glucoside 1% 15% Guanidine・HCl 1M 6M
Octylβ-thioglucopyranoside 1% 15% Urea 4M 8M
Triton®X-100 0.1% 15% Thiourea 2M 2M
Tween®-20 0.05% 15% Buffer  
CTAB 0.005% 2% Glycine pH2.8 1M 0.1mM*
Deoxycholic Acid 0.025% 7.5% HEPES pH7.5 0.5M 1M
SDS 0.01% 2% MES pH6.1 1M 1M
CHAPS 0.5% 15% MOPS pH7.2 1M 1M
CHAPSO 0.5% 15% PBS 5X 5X
還元剤   Sodium Acetate pH5.2 0.75M 1.5M
DTT 0.5M 0.5M Sodium Bicarbonate 0.25M 0.5M
2-Mercaptoethanol 5M 1.25M TBS;Tris(25mM),NaCl(137mM) 5X 5X
TCEP pH7.6 0.25M 0.25M Tris-HCl pH8 2M 4M
Glutathione pH7 125mM 125mM その他  
キレート剤   KCl 1M 4M
EDTA 0.25M 25mM* NaCl 1.25M 5M
EGTA 0.25M 5mM* MgCl2 0.5M 4.5M
Sodium Citrate 0.25M 100mM* HCl 0.1M 10mM*
 

▲戻る

参考情報

本製品を加え遠心操作を行う事で、タンパク質を沈殿させ、妨害物質を除去します。沈殿後のタンパク質にプロテインアッセイCBB溶液を直接添加する事で、定量が可能です。
尚、本製品により0.2~1.0mg/ml濃度のタンパク質溶液を沈殿できます。
*詳細は製品添付文書をご参照ください。

▲戻る

価格表
製品名規格貯法製品番号容量価格
Protein Assay CBB Clean Up Kit SP 室温 11611-60 1 kit(250回) 9,300

 ※記載の内容は、'13年3月現在の情報に基づいております。

Viewing all 1104 articles
Browse latest View live